The first cellular product candidate derived from Cellvation’s proprietary bio-reactor (CEVA-D) will initially be studied in adults and children with severe TBI.
The first cellular product candidate derived from Cellvation’s proprietary bio-reactor (CEVA-D) will initially be studied in adults and children with severe TBI.